Buprenorphine Patches in Diabetic Peripheral Neuropathy
Transdermal buprenorphine may be an effective therapy for diabetic peripheral neuropathic pain (DPNP). However the treatment was associated with a high rate of adverse events, mostly nausea and/or vomiting. The findings come from a newly published multi-center, randomized, double-blind, placebo-controlled, parallel-group trial. Ninety-three patients with type 1 or 2 diabetes were enrolled and received either buprenorphine (5μg/h) or placebo patches. All the patients had been experiencing moderate to severe DPNP for a minimum of 6 months on maximal tolerated conventional therapy. The dose was titrated to effect to a maximum of 40μg/h for the study. Results showed that of those…